The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Effect of Core and Coating Composition on Drug Release from Directly Compressed Time-Controlled Release Tablets
The authors prepared and tested press-coated tablets with various weight ratios of ethylcellulose to hydroxypropylcellulose (HPC) and various ratios of two different batches of HPC as an outer coating shell and fillers in core tablets. The tablets were examined for changes in time lag and release patterns of salbutamol sulfate.


Pharmaceutical Technology


Preparation of press-coated tablets. The press-coated tablets were prepared according to the method described by Fukui (8). All powder mixtures were passed through a sieve no. 44, and 150 mg of the powder mixture was used for the upper and lower shells. Press coating was performed using a rotary tablet machine. Half (150 mg) of the powder was filled into the die to make a powder bed, and the core tablet was placed manually in the center. The remaining half of the coating material was used to fill the die, and the contents were compressed under a sufficient compression force (total weight = 375 mg) using a concave punch 10 mm in diameter to keep the hardness of the coated tablet at 10 0.34 kg/cm2 .

Formulations for the outer shell of press-coated tablets. The formulation of the outer shell for the press-coated tablet using core tablet containing 4% Ac-Di-Sol and Starlac or Avicel PH 101 as filler was respectively prepared according to the following formulas:

  • rupturable polymer (EC) combined with erodible polymer (HPC EXF): weight ratios of HPC EXF to EC N 22 F were 0:100%, 12.5:87.5%, 25:75%, 50:50%, 75:25%, 87.5:12.5%, and 100:0% w/w;
  • gellable polymer (HPC HF) combined with erodible polymer (HPC EXF): weight ratios of HPC HF to HPC EXF were 0:100%, 12.5:87.5%, 25:75%, 50:50%, 75:25%, 87.5:12.5%, and 100:0% w/w.

In vitro dissolution study. To verify how the composition of the core and the barriers interferes with the drug-release profile from the cores, the in vitro release behavior of the uncoated cores and press-coated tablets were tested. The test was carried out in a USP dissolution paddle assembly (model DT 60, Veego, India) at 37 0.5 C using 0.1 N HCl (first fluid; simulated gastric fluid) for the first 2 h. The tablets then were transfered to 6.8 pH phosphate buffer (second fluid; simulated intestinal fluid) solution. Aliquots of dissolution fluid were removed at specified time intervals and assayed for the amount of salbutamol sulfate released by a spectrophotometer (UV 1700, Shimadzu, Japan) at wavelengths of 224.5 and 225 nm for 0.1 N HCl and 6.8 pH phosphate buffer, respectively. The in vitro release patterns of the cores were studied visually by taking images of the tablets in a Petri plate containing dissolution medium. All dissolution studies were performed in triplicate (n = 3) to obtained mean and standard deviation.

Erosion study of press-coated tablets. The erosion study of press-coated tablets was designed to determine whether the prevailing release mechanism of salbutamol sulfate from the coated devices depends on the types of core composition. The percentage of erosion from the press-coated tablets was determined in the dissolution medium just before lag time. At predetermined time points (before lag time), the tablets were removed from the dissolution medium, carefully blotted with tissue paper to remove surface water, and weighed. The percentage of erosion was calculated as follows (9):








in which Wt is the weight of wet tablet at time t and W0 is the weight of the dry coated tablet.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here